N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,116 Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Paroxysmal Supraventricular Tachycardia
Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants
N/A N=3 Cardioneuroablation for Neurocardiogenic Syncope
Neurocardiogenic Syncope · Vasovagal Syncope
Primary: Syncope Recurrence Rate
N/A N=48 REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients
Ventricular Tachycardia
Primary: Time to First Event Requiring ICD Therapy or Incessant VT — 177.2; 148.66 days
N/A N=32 Trial of Continuous Versus Cyclic Stimulation in Interstim Therapy
Urge Incontinence
Primary: Number of Micturitions in 24 Hours
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
Phase 2 N=4 Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
Chronic Heart Failure
Primary: Peak Exercise Wedge Pressure — 44; 34 Mmhg
N/A N=24 Noninvasive Neuromodulation to Reserve Diastolic Dysfunction
Heart Failure, Diastolic
Primary: Echocardiographic Markers of Diastolic Dysfunction — -21.2; -23.0 percent
Phase 2 N=20 Nitrate Effect on Exercise Capacitance
Fontan
Primary: Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period. — 16 Participants
N/A N=17 REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation
Ventricular Tachycardia
Primary: Freedom From First Event Requiring ICD Therapy — 62.5; 50; 62.5; 37.5 probability of freedom
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
N/A N=31 Comparison of Motor and Sensory Response With Interstim Stimulation
Overactive Bladder · Urgency-Frequency
Primary: Percent of Symptoms With Improvement of Leaks Reported — 14.4; 19.8; 18.2 Percent change in leaks
N/A N=30 SinuSonic for ETD and Facial Pain: Acoustic Vibration + Oscillating Expiratory Pressure
Eustachian Tube Dysfunction · Facial Pain
Primary: Eustachian Tube Dysfunction (ETD) Symptom Visual Analog Scale (VAS) - Total Score — 59.6 score on a scale
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17
Phase 2 N=30 Nicotinamide Riboside in Systolic Heart Failure
Heart Failure, Systolic
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3.1; 3.2 events/participant
Phase 1 N=36 Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium
Sinusitis
Primary: Patency of Treated Area — 95 percentage of ostia treated
N/A N=55 Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation
ACC/AHA/NASPE Class 1, IIa or IIb Indications
Primary: Conversion of Induced Ventricular Fibrillation — 52 Participants
N/A N=16 Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction
Diastolic Dysfunction
Primary: Change in Left Ventricle Mean Diastolic Pressure — 3.3 mmHg
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
Phase 3 N=33 SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI
Atrial Fibrillation
Primary: LA Fibrosis — 24.6; 16.8 percentage of fibrosis
N/A N=2,101 Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II
Standard Bradycardia Pacing Indication
Primary: Percentage of Participants With Complications in the General Pacemaker Population — 3.33 percentage of subjects
N/A N=85 Dipole Density Mapping in Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants
Phase 4 N=77 ISSUE3: International Study on Syncope of Uncertain Etiology 3
Syncope
Primary: Syncope Recurrence Rate — 57; 25 percentage of participants — p=0.04
N/A N=27 Effect of Dietary Sodium Intake on Vascular Endothelium
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change
N/A N=30 Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction
Primary: Change in Coronary Flow Reserve (CFR) — 3.04 ratio — p=0.0137
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 2 N=199 Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Paroxysmal Supraventricular Tachycardia (PSVT)
Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05